(Q35025931)

English

Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models

scientific article

Statements

Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models (English)
Konstantin H Dragnev
Fabrizio Galimberti
Gregory J Tsongalis

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit